Logo image of ONMD

ONEMEDNET CORP (ONMD) Stock Fundamental Analysis

NASDAQ:ONMD - Nasdaq - US68270C1036 - Common Stock - Currency: USD

0.551  -0.08 (-12.54%)

After market: 0.5395 -0.01 (-2.09%)

Fundamental Rating

0

Taking everything into account, ONMD scores 0 out of 10 in our fundamental rating. ONMD was compared to 36 industry peers in the Health Care Technology industry. ONMD has a bad profitability rating. Also its financial health evaluation is rather negative. ONMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ONMD has reported negative net income.
In the past year ONMD has reported a negative cash flow from operations.
In the past 5 years ONMD always reported negative net income.
ONMD had negative operating cash flow in 4 of the past 5 years.
ONMD Yearly Net Income VS EBIT VS OCF VS FCFONMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

ONMD's Return On Assets of -572.92% is on the low side compared to the rest of the industry. ONMD is outperformed by 97.22% of its industry peers.
Industry RankSector Rank
ROA -572.92%
ROE N/A
ROIC N/A
ROA(3y)-1920.19%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONMD Yearly ROA, ROE, ROICONMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONMD Yearly Profit, Operating, Gross MarginsONMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

0

2. Health

2.1 Basic Checks

ONMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ONMD has been increased compared to 1 year ago.
The debt/assets ratio for ONMD has been reduced compared to a year ago.
ONMD Yearly Shares OutstandingONMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ONMD Yearly Total Debt VS Total AssetsONMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -112.77, we must say that ONMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -112.77, ONMD is doing worse than 97.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -112.77
ROIC/WACCN/A
WACC7.59%
ONMD Yearly LT Debt VS Equity VS FCFONMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M -10M -15M

2.3 Liquidity

ONMD has a Current Ratio of 0.09. This is a bad value and indicates that ONMD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.09, ONMD is not doing good in the industry: 97.22% of the companies in the same industry are doing better.
A Quick Ratio of 0.09 indicates that ONMD may have some problems paying its short term obligations.
ONMD's Quick ratio of 0.09 is on the low side compared to the rest of the industry. ONMD is outperformed by 97.22% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
ONMD Yearly Current Assets VS Current LiabilitesONMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

0

3. Growth

3.1 Past

ONMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.78%, which is quite impressive.
Looking at the last year, ONMD shows a very negative growth in Revenue. The Revenue has decreased by -72.71% in the last year.
The Revenue for ONMD have been decreasing by -16.18% on average. This is quite bad
EPS 1Y (TTM)82.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.37%
Revenue 1Y (TTM)-72.71%
Revenue growth 3Y-16.18%
Revenue growth 5YN/A
Sales Q2Q%-44.76%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONMD Yearly Revenue VS EstimatesONMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 200K 400K 600K 800K 1M

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONMD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONMD Price Earnings VS Forward Price EarningsONMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONMD Per share dataONMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ONMD!.
Industry RankSector Rank
Dividend Yield N/A

ONEMEDNET CORP

NASDAQ:ONMD (7/3/2025, 7:58:15 PM)

After market: 0.5395 -0.01 (-2.09%)

0.551

-0.08 (-12.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners16.19%
Inst Owner Change15.51%
Ins Owners37.13%
Ins Owner Change0%
Market Cap16.84M
AnalystsN/A
Price TargetN/A
Short Float %0.7%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.66
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.02
BVpS-0.54
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -572.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1920.19%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5086.21%
Cap/Sales 554.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -112.77
F-Score4
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)1855.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)156.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.37%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-72.71%
Revenue growth 3Y-16.18%
Revenue growth 5YN/A
Sales Q2Q%-44.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1376.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-954.86%
OCF growth 3YN/A
OCF growth 5YN/A